Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

Key Points

MAIN FINDING: The study demonstrates significant differences in cytokines and immune cells in patients with and without major pathological response (MPR).
KEY EVIDENCE: Patients who achieved complete pathological response (pCR) had distinct immune cell profiles compared to non-pCR patients, highlighting treatment effects.
APPROACH: The trial involved measuring peripheral cytokines and immune cells in patients undergoing chemotherapy and avelumab treatment pre- and post-surgery.
SIGNIFICANCE: These findings may inform future therapeutic strategies for improving outcomes in gastric cancer treatment.

Phase II trial assesses cytokine and immune cell changes in gastric cancer patients, suggesting potential for enhanced treatment efficacy.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Alsina et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share